Biocon Receives EMA Approval for New Insulin Drug Product Fill Finish Unit in Malaysia
Biocon Ltd has received approval from the European Medicines Agency (EMA) to establish a new drug product fill finish line for Semglee® (insulin glargine). The manufacturing unit is situated at the company's insulin production facility located in Malaysia.This development enhances the company's manufacturing capabilities for its insulin products. Biocon expects that commercial supplies to Europe from this dedicated production line will begin during the second quarter of fiscal year 2027 (Q2FY27).
| Detail | Information |
|---|---|
| Product Involved | Semglee® (insulin glargine) |
| Regulatory Authority | European Medicines Agency (EMA) |
| Manufacturing Location | Malaysia |
| Expected Supply Timeline | Q2FY27 |
BIOCON Stock Price Movement
On Wednesday, Biocon Limited shares slipped by 0.83% to settle at ₹433.65. The stock hit a new 52-week high during the session as 10.23 million shares changed hands.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.